CY1107314T1 - Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη - Google Patents
Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονηInfo
- Publication number
- CY1107314T1 CY1107314T1 CY20061101704T CY061101704T CY1107314T1 CY 1107314 T1 CY1107314 T1 CY 1107314T1 CY 20061101704 T CY20061101704 T CY 20061101704T CY 061101704 T CY061101704 T CY 061101704T CY 1107314 T1 CY1107314 T1 CY 1107314T1
- Authority
- CY
- Cyprus
- Prior art keywords
- classification
- patients affected
- composite integrity
- education
- therapeutic
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση περιλαμβάνει μεθόδους πρόληψης και θεραπευτικής αγωγής σκλήρυνσης κατά πλάκας χορηγώντας σε ασθενείς χρείζοντες αυτών θεραπευτικά αποτελεσματική ποσότητα IFN-con, μόνη της ή σε συνδυασμό με άλλον δραστικό παράγοντα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/911,893 US6013253A (en) | 1997-08-15 | 1997-08-15 | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
EP98933344A EP1003546B1 (en) | 1997-08-15 | 1998-07-15 | Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107314T1 true CY1107314T1 (el) | 2012-11-21 |
Family
ID=25431058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101704T CY1107314T1 (el) | 1997-08-15 | 2006-11-27 | Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη |
Country Status (18)
Country | Link |
---|---|
US (1) | US6013253A (el) |
EP (1) | EP1003546B1 (el) |
JP (1) | JP3813440B2 (el) |
KR (1) | KR100415636B1 (el) |
CN (1) | CN1183963C (el) |
AT (1) | ATE338563T1 (el) |
AU (1) | AU741074B2 (el) |
CA (1) | CA2299361C (el) |
CY (1) | CY1107314T1 (el) |
DE (1) | DE69835823T2 (el) |
DK (1) | DK1003546T3 (el) |
ES (1) | ES2267188T3 (el) |
HK (1) | HK1030157A1 (el) |
HU (1) | HU229045B1 (el) |
IL (2) | IL134345A0 (el) |
PT (1) | PT1003546E (el) |
TW (1) | TW474817B (el) |
WO (1) | WO1999008702A1 (el) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
AU2002303856A1 (en) | 2001-05-24 | 2002-12-03 | Neuronz Limited | Gpe analogs and peptidomimetics |
US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
DE60316407T2 (de) * | 2002-02-06 | 2008-06-19 | Ares Trading S.A. | Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit |
EP3064215A1 (en) * | 2002-10-16 | 2016-09-07 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
DE102004008168B4 (de) * | 2004-02-19 | 2015-12-10 | Voxeljet Ag | Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung |
EP1748788A1 (en) * | 2004-05-17 | 2007-02-07 | Ares Trading S.A. | Hydrogel interferon formulations |
MXPA06014079A (es) | 2004-06-01 | 2007-02-15 | Ares Trading Sa | Metodo para estabilizar proteinas. |
EP1750751B1 (en) * | 2004-06-01 | 2013-04-10 | Ares Trading S.A. | Stabilized interferon liquid formulations |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
BG66458B1 (bg) | 2005-03-21 | 2014-10-31 | Иван Иванов | Средство за конкурентно инхибиране на ендогенен гама интерферон |
US20100028296A1 (en) * | 2005-05-02 | 2010-02-04 | Chavez Raymond A | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
LT1917276T (lt) | 2005-08-26 | 2018-05-25 | Ares Trading S.A. | Glikozilinto interferono beta gavimo būdas |
CN101282740A (zh) * | 2005-09-01 | 2008-10-08 | 阿雷斯贸易股份有限公司 | 视神经炎的治疗 |
PL2026832T3 (pl) | 2006-05-24 | 2012-08-31 | Merck Serono Sa | Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego |
CN101878043A (zh) * | 2007-12-20 | 2010-11-03 | 默克雪兰诺有限公司 | PEG-干扰素-β制剂 |
US9359421B2 (en) | 2008-04-08 | 2016-06-07 | Tigo Gmbh | Suppressor of the endogenous interferon-gamma |
BG66517B1 (bg) | 2008-04-08 | 2016-02-29 | Tigo Gmbh | Супресор на ендогенния човешки гама - интерферон |
WO2013008102A2 (en) | 2011-07-14 | 2013-01-17 | R.E.D. Laboratories N.V../ S.A. | Methods and compositions for evaluating and/or treating chronic immune diseases |
RS59735B1 (sr) | 2013-07-18 | 2020-02-28 | Xalud Therapeutics Inc | Sastav za tretman upalnih bolesti zglobova |
BG67190B1 (bg) | 2017-03-29 | 2020-11-16 | Tigo Gmbh | Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
AU651955B2 (en) * | 1989-11-29 | 1994-08-11 | Amgen, Inc. | Production of recombinant human interleukin-1 inhibitor |
WO1991017184A1 (en) * | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
CA2094275C (en) * | 1990-10-17 | 2003-06-03 | Lawrence M. Blatt | Methods and compositions for the treatment of cell proliferation disorders |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5858355A (en) * | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
CA2106079C (en) * | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
DK0639079T3 (da) * | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
CZ291261B6 (cs) * | 1992-09-17 | 2003-01-15 | Amgen Inc. | Farmaceutická kompozice pro léčení nemocí zprostředkovaných interleukinem-1 |
US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
EP0701563A4 (en) * | 1993-03-08 | 1997-07-02 | Univ Pittsburgh | GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL |
EP0689449B1 (fr) * | 1993-03-19 | 2002-10-30 | Vacsyn S.A. | Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
FR2706772A1 (en) * | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
AU1916295A (en) * | 1994-02-08 | 1995-08-29 | Amgen, Inc. | Oral delivery of chemically modified proteins |
-
1997
- 1997-08-15 US US08/911,893 patent/US6013253A/en not_active Expired - Lifetime
-
1998
- 1998-07-15 AT AT98933344T patent/ATE338563T1/de active
- 1998-07-15 CA CA002299361A patent/CA2299361C/en not_active Expired - Fee Related
- 1998-07-15 DE DE69835823T patent/DE69835823T2/de not_active Expired - Lifetime
- 1998-07-15 ES ES98933344T patent/ES2267188T3/es not_active Expired - Lifetime
- 1998-07-15 DK DK98933344T patent/DK1003546T3/da active
- 1998-07-15 EP EP98933344A patent/EP1003546B1/en not_active Expired - Lifetime
- 1998-07-15 PT PT98933344T patent/PT1003546E/pt unknown
- 1998-07-15 WO PCT/US1998/014622 patent/WO1999008702A1/en active IP Right Grant
- 1998-07-15 HU HU0002755A patent/HU229045B1/hu unknown
- 1998-07-15 IL IL13434598A patent/IL134345A0/xx active IP Right Grant
- 1998-07-15 AU AU83006/98A patent/AU741074B2/en not_active Expired
- 1998-07-15 CN CNB988081520A patent/CN1183963C/zh not_active Expired - Fee Related
- 1998-07-15 JP JP2000509439A patent/JP3813440B2/ja not_active Expired - Lifetime
- 1998-07-15 KR KR10-2000-7001097A patent/KR100415636B1/ko not_active IP Right Cessation
- 1998-07-29 TW TW087112465A patent/TW474817B/zh not_active IP Right Cessation
-
2000
- 2000-02-02 IL IL134345A patent/IL134345A/en not_active IP Right Cessation
-
2001
- 2001-02-16 HK HK01101141A patent/HK1030157A1/xx not_active IP Right Cessation
-
2006
- 2006-11-27 CY CY20061101704T patent/CY1107314T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU741074B2 (en) | 2001-11-22 |
CN1183963C (zh) | 2005-01-12 |
EP1003546B1 (en) | 2006-09-06 |
KR100415636B1 (ko) | 2004-01-24 |
HU229045B1 (en) | 2013-07-29 |
CN1267225A (zh) | 2000-09-20 |
PT1003546E (pt) | 2006-12-29 |
IL134345A0 (en) | 2001-04-30 |
HK1030157A1 (en) | 2001-04-27 |
JP2001515047A (ja) | 2001-09-18 |
ATE338563T1 (de) | 2006-09-15 |
DE69835823D1 (de) | 2006-10-19 |
EP1003546A1 (en) | 2000-05-31 |
WO1999008702A1 (en) | 1999-02-25 |
DE69835823T2 (de) | 2007-08-09 |
JP3813440B2 (ja) | 2006-08-23 |
DK1003546T3 (da) | 2006-10-30 |
HUP0002755A3 (en) | 2001-11-28 |
CA2299361A1 (en) | 1999-02-25 |
IL134345A (en) | 2011-03-31 |
TW474817B (en) | 2002-02-01 |
HUP0002755A2 (hu) | 2000-12-28 |
CA2299361C (en) | 2009-09-29 |
US6013253A (en) | 2000-01-11 |
KR20010030563A (ko) | 2001-04-16 |
AU8300698A (en) | 1999-03-08 |
ES2267188T3 (es) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107314T1 (el) | Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη | |
CY1107615T1 (el) | Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων | |
CY1118429T1 (el) | Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου | |
CY1110405T1 (el) | Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων | |
CY1107586T1 (el) | Θepαπεiα για τη δυσκοιλιoτητα | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
EA200300628A1 (ru) | Соединения, специфические к аденозиновому a, aи aрецептору, и их применение | |
CY1106156T1 (el) | Νεα χρηση βουδεσονιδης και φορμοτepολης | |
NO20002785L (no) | Adamantanderivater | |
NO20002786D0 (no) | Adamantanderivater | |
TR200000756T2 (tr) | Davranış bozukluğu tedavisi. | |
NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
CY1107687T1 (el) | Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας | |
DK0680323T3 (da) | Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer. | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
PT862454E (pt) | Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados | |
DK0799618T3 (da) | Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer | |
PT983300E (pt) | Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia | |
CY1105624T1 (el) | Αντιγλαυκωματικο μεσο και χρηση αυτου | |
ATE268170T1 (de) | Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz | |
BR9801839A (pt) | Medicamento analgésico e aplicação de (+) -0-demetiltramadol. | |
BR9708037A (pt) | Método para o tratamento de abuso de substância |